CXXC1

Across TCGA pan-cancer cohorts, CXXC1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CXXC1 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in prostate adenocarcinoma (PRAD), where higher CXXC1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated CXXC1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PRAD, UCEC, and ACC are the cancer types where CXXC1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
ACC	OS	Median	All	0.217	0.633	.045	4	view →
LUSC	DFS	Median	II,III,IV	0.199	0.748	.033	3	view →
HNSC	OS	Median	IV	1.000	0.350	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CXXC1–PRAD (DFS)

Open the PRAD breakdown →